Barclays’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10K | Sell |
1,155
-8,018
| -87% | -$69.4K | ﹤0.01% | 4154 |
|
|
2025
Q1 | $99K | Sell |
9,173
-3,746
| -29% | -$40.4K | ﹤0.01% | 3694 |
|
|
2024
Q4 | $165K | Buy |
12,919
+888
| +7% | +$11.3K | ﹤0.01% | 3599 |
|
|
2024
Q3 | $332K | Buy |
12,031
+9,116
| +313% | +$252K | ﹤0.01% | 3223 |
|
|
2024
Q2 | $84K | Sell |
2,915
-4,412
| -60% | -$127K | ﹤0.01% | 3456 |
|
|
2024
Q1 | $326K | Sell |
7,327
-5,827
| -44% | -$259K | ﹤0.01% | 3076 |
|
|
2023
Q4 | $510K | Buy |
13,154
+892
| +7% | +$34.6K | ﹤0.01% | 2985 |
|
|
2023
Q3 | $362K | Buy |
12,262
+2,349
| +24% | +$69.3K | ﹤0.01% | 2726 |
|
|
2023
Q2 | $630K | Sell |
9,913
-2,350
| -19% | -$149K | ﹤0.01% | 2451 |
|
|
2023
Q1 | $579K | Sell |
12,263
-4,507
| -27% | -$213K | ﹤0.01% | 2539 |
|
|
2022
Q4 | $1.16M | Buy |
16,770
+10,035
| +149% | +$697K | ﹤0.01% | 2021 |
|
|
2022
Q3 | $988K | Buy |
6,735
+6,301
| +1,452% | +$924K | ﹤0.01% | 2139 |
|
|
2022
Q2 | $57K | Sell |
434
-1,198
| -73% | -$157K | ﹤0.01% | 3681 |
|
|
2022
Q1 | $164K | Buy |
+1,632
| New | +$164K | ﹤0.01% | 3432 |
|